Pluristem Therapeutics, Inc. (NASDAQ:PSTI) received a $2.00 target price from analysts at Maxim Group in a research note issued on Wednesday. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Maxim Group’s price target points to a potential upside of 68.07% from the company’s previous close.

Separately, HC Wainwright reiterated a “buy” rating and set a $3.50 target price on shares of Pluristem Therapeutics in a research report on Monday, May 15th.

Shares of Pluristem Therapeutics (NASDAQ:PSTI) traded up 5.31% during trading on Wednesday, hitting $1.19. 1,006,958 shares of the stock were exchanged. Pluristem Therapeutics has a 52 week low of $1.04 and a 52 week high of $1.85. The firm’s market capitalization is $114.63 million. The firm has a 50 day moving average price of $1.20 and a 200 day moving average price of $1.27.

TRADEMARK VIOLATION NOTICE: This article was first reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international copyright law. The legal version of this article can be read at https://www.americanbankingnews.com/2017/08/16/pluristem-therapeutics-inc-psti-given-a-2-00-price-target-by-maxim-group-analysts.html.

A number of large investors have recently bought and sold shares of PSTI. Harel Insurance Investments & Financial Services Ltd. increased its stake in Pluristem Therapeutics by 46.0% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 92,000 shares of the biotechnology company’s stock valued at $135,000 after buying an additional 29,000 shares in the last quarter. Jane Street Group LLC increased its stake in Pluristem Therapeutics by 62.4% in the first quarter. Jane Street Group LLC now owns 108,830 shares of the biotechnology company’s stock valued at $134,000 after buying an additional 41,796 shares in the last quarter. Menora Mivtachim Holdings LTD. acquired a new stake in Pluristem Therapeutics during the first quarter valued at approximately $1,230,000. Finally, Renaissance Technologies LLC increased its stake in Pluristem Therapeutics by 8.6% in the fourth quarter. Renaissance Technologies LLC now owns 1,424,800 shares of the biotechnology company’s stock valued at $2,037,000 after buying an additional 113,300 shares in the last quarter. Institutional investors and hedge funds own 3.81% of the company’s stock.

Pluristem Therapeutics Company Profile

Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.

Receive News & Ratings for Pluristem Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.